Who makes UBX1325 injection 50 μL?

UBX1325 injection 50 μL is developed by Unity Biotechnology, Inc..

What development phase is UBX1325 injection 50 μL in?

UBX1325 injection 50 μL is in Phase 2.

Last reviewed 2026-04-19 · How we verify

UBX1325 injection 50 μL

Unity Biotechnology, Inc. · Phase 2 active Small molecule

At a glance

Generic name	UBX1325 injection 50 μL
Sponsor	Unity Biotechnology, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (PHASE2)
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) (PHASE2)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

UBX1325 injection 50 μL CI brief — competitive landscape report
UBX1325 injection 50 μL updates RSS · CI watch RSS
Unity Biotechnology, Inc. portfolio CI